Drug Profile
Reparixin - Dompe Farmaceutici
Alternative Names: DF-1681Y; Repertaxin; Repertaxin L-Lysine saltLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Dompe Farmaceutici
- Developer Dompe Farmaceutici; Fox Chase Cancer Center; Icahn School of Medicine at Mount Sinai; SatRx; University of Michigan Comprehensive Cancer Center
- Class Antineoplastics; Benzeneacetamides; Small molecules; Sulfonamides
- Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Community-acquired pneumonia; COVID-19 pneumonia; Delayed graft function
- Phase II Adult respiratory distress syndrome; Essential thrombocythaemia; Fatigue; Liver transplant rejection; Myelofibrosis; Polycythaemia vera; Triple negative breast cancer
- No development reported Breast cancer
- Discontinued Cerebral ischaemia
Most Recent Events
- 27 Jun 2023 Phase-II clinical trials in Essential thrombocythaemia (Treatment-experienced) in USA (PO) (NCT05835466)
- 27 Jun 2023 Phase-II clinical trials in Myelofibrosis (Treatment-experienced) in USA (PO) (NCT05835466)
- 27 Jun 2023 Phase-II clinical trials in Polycythaemia vera (Treatment-experienced) in USA (PO) (NCT05835466)